Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has reported positive neuroimaging results in 80% of non-active Secondary Progressive Multiple Sclerosis patients treated with intranasal foralumab over six months. The company is expanding its Expanded Access Program to include 20 additional patients and has applied for FDA Orphan Drug Designation for the treatment. These developments indicate significant progress in the company’s innovative immunomodulation therapy program for multiple sclerosis.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
